1.34

0.25% -0.00

Igm Biosciences Inc (IGMS)

Overview News Price History Option Chain Financials Discussions Forecast

Igm Biosciences Inc stock is traded at $1.34, with a volume of 60,238. It is down -0.25% in the last 24 hours and down -15.41% over the past month. IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Previous Close:

$1.34

Open:

$1.34

24h Volume:

60,238

Relative Volume:

0.14

Market Cap:

$79.68M

Revenue:

$2.91M

Net Income/Loss:

$-220.40M

P/E Ratio:

-0.3681

EPS:

-3.64

Net Cash Flow:

$-176.15M

1W Performance:

-3.14%

1M Performance:

-15.41%

6M Performance:

-86.59%

1Y Performance:

-90.24%

1-Day Range:

$1.2962

$1.40

1-Week Range:

$1.29

$1.44

52-Week Range:

$1.26

$22.50

Igm Biosciences Inc Stock (IGMS) Company Profile

Name

Igm Biosciences Inc

Sector

Healthcare (1189)

Industry

Biotechnology (675)

Phone

650-965-7873

Address

325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW

Employee

198

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

IGMS's Discussions on Twitter

Compare IGMS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IGMS Igm Biosciences Inc	1.34	79.68M	2.91M	-220.40M	-176.15M	-3.64
VRTX Vertex Pharmaceuticals Inc	477.36	121.85B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	697.91	76.83B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	618.58	37.96B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	242.92	30.69B	2.25B	-278.16M	-42.59M	-2.17
ONC Beone Medicines Ltd Adr	268.98	29.71B	3.32B	-860.46M	-1.04B	-8.32

Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-10-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jan-10-25	Downgrade	Guggenheim	Buy → Neutral
Jan-10-25	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jan-10-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jan-10-25	Downgrade	Stifel	Buy → Hold
Dec-06-24	Initiated	BMO Capital Markets	Outperform
Oct-01-24	Downgrade	JP Morgan	Neutral → Underweight
Oct-01-24	Downgrade	Truist	Buy → Hold
Feb-09-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral
Dec-07-23	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-09-22	Resumed	Jefferies	Buy
Oct-17-22	Initiated	JP Morgan	Neutral
Aug-29-22	Initiated	BofA Securities	Buy
Dec-13-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-05-21	Upgrade	Wedbush	Neutral → Outperform
Aug-26-21	Initiated	Morgan Stanley	Overweight
Jan-29-21	Initiated	RBC Capital Mkts	Outperform
Jan-19-21	Reiterated	H.C. Wainwright	Buy
Dec-22-20	Downgrade	Wedbush	Outperform → Neutral
Jul-17-20	Initiated	Robert W. Baird	Outperform
Jul-01-20	Initiated	H.C. Wainwright	Buy
May-28-20	Initiated	SunTrust	Buy
Apr-22-20	Initiated	Wedbush	Outperform
Oct-14-19	Initiated	Guggenheim	Buy
Oct-14-19	Initiated	Jefferies	Buy
Oct-14-19	Initiated	Piper Jaffray	Overweight
Oct-14-19	Initiated	Stifel	Buy

View All

Igm Biosciences Inc Stock (IGMS) Latest News

02:47 AM

IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Rating of “Reduce” from Brokerages - Defense World

02:47 AM

Feb 27, 2025